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RESEARCH ARTICLE Open Access
Can incontinence be cured? A systematic
review of cure rates
Rob Riemsma1* , Suzanne Hagen2, Ruth Kirschner-Hermanns3, Christine Norton4, Helle Wijk5, Karl-Erik Andersson6,
Christopher Chapple7, Julian Spinks8, Adrian Wagg9, Edward Hutt10, Kate Misso1, Sohan Deshpande1,
Jos Kleijnen1,11 and Ian Milsom12
Abstract
Background: Incontinence constitutes a major health problem affecting millions of people worldwide. The present
study aims to assess cure rates from treating urinary (UI) or fecal incontinence (FI) and the number of people who
may remain dependent on containment strategies.
Methods: Medline, Embase, PsycINFO, Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, and PEDro
were searched from January 2005 to June 2015. Supplementary searches included conference abstracts and trials
registers (2013–2015). Included studies had patients≥ 18 years with UI or FI, reported treatment cure or success
rates, had ≥ 50 patients treated with any intervention recognized in international guideline algorithms, a follow-
up ≥ 3 months, and were published from 2005 onwards. Title and abstract screening, full paper screening, data
extraction and risk-of-bias assessment were performed independently by two reviewers. Disagreements were
resolved through discussion or referral to a third reviewer where necessary. A narrative summary of included
studies is presented.
Results: Most evidence was found for UI: Surgical interventions for stress UI showed a median cure rate of 82.3%
(interquartile range (IQR), 72–89.5%); people with urgency UI were mostly treated using medications (median cure
rate for antimuscarinics = 49%; IQR, 35.6–58%). Pelvic floor muscle training and bulking agents showed lower cure
rates for UI. Sacral neuromodulation for FI had a median cure rate of 38.6% (IQR, 35.6–40.6%).
Conclusions: Many individuals were not cured and hence may continue to rely on containment. No studies were
found assessing success of containment strategies. There was a lack of data in the disabled and in those with
neurological diseases, in the elderly and those with cognitive impairment. Surgical interventions were effective for
stress UI. Other interventions for UI and FI showed lower cure rates. Many individuals are likely to be reliant on
containment strategies.
PROSPERO Registration: PROSPERO registration number: CRD42015023763.
Keywords: Incontinence, Systematic review, Cure rates
Background
Urinary incontinence (UI) constitutes a major health
problem affecting the lives of an estimated 400 million
persons worldwide [1–6]. The prevalence of UI increases
with age and is highly prevalent in the elderly and those
with cognitive impairment [5]. Fecal incontinence (FI)
occurs in up to 6% of those younger than 40 years
increasing to 15% in older individuals [1, 2, 4]. Com-
bined FI and UI has been reported in 10% of women
and in 6–10% of men living in the community, increas-
ing to almost 50% in nursing home residents [7–9].
Incontinence is also more prevalent in men and women
affected by various neurological illnesses, e.g., multiple
sclerosis, spina bifida, Parkinson’s disease, and stroke [5].
The World Health Organization has acknowledged
incontinence as a set of diseases (International Classifi-
cation of Diseases ICD-10) and the International
Classification of Functionality recognizes the associated
* Correspondence: rob@systematic-reviews.com
1Kleijnen Systematic Reviews Ltd, Unit 6, Escrick Business Park, Riccall Road,
Escrick, York YO19 6FD, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Riemsma et al. BMC Medicine  (2017) 15:63 
DOI 10.1186/s12916-017-0828-2
extreme disablement [5]. Global demographic trends
suggest that the incidence of both UI and FI will rise in
the coming years, with a significant health and social
burden as well as an increased economic cost for both
patients and health service payers [5].
Incontinence has a profound impact on well-being
and quality of life, causing social embarrassment,
reduced employment and work productivity, and pre-
venting many people from participating in paid or
unpaid activities [5, 10, 11]. Further, it has a negative
influence on sexual health [11–13]. There is also a
significant impact on caregivers and, for older people,
incontinence significantly increases the likelihood of
institutionalization [5]. Incontinence presents a sig-
nificant health and economic burden comparable with
common major diseases such as arthritis and pneu-
monia [14–17].
Various management options are available for UI, many
of which are given in combination, including behavioral
techniques, pelvic floor muscle training (PFMT), medica-
tion, surgery, nerve stimulation, and containment prod-
ucts such as pads and catheters [18]. Treatment for FI
includes diet adaptation, medication, biofeedback, PFMT,
surgery, sacral or tibial nerve stimulation, and contain-
ment products [19].
It is important to guide health service payers and
providers as to how continence care might best be
configured to deliver efficient, guideline-compliant, high-
quality patient care [12]. It has previously been suggested
that the provision of continence management be consid-
ered for four patient profiles, namely those with (1) UI, (2)
FI, (3) disabled/neurological illnesses, or (4) the elderly/
cognitively impaired [20].
Given the impact of incontinence, it is important to
know how large the residual problem is following treat-
ment. Although there are numerous systematic reviews
of the relative effects of various treatments, there is no
review which addresses cure rates following treatment.
The aim of this systematic review was to establish cure
rates based on extent of leakage after treating incontin-
ence for each of the four pre-defined patient profiles and
to assess the number of people still dependent on
containment (including behavioral strategies and con-
tainment products) following treatment in order to live
a normal life.
Methods
Objectives
The objectives of this review were to describe cure rates
of treatment in patients with UI or FI and estimate how
many people remained dependent on containment strat-
egies. A further objective was to determine the extent to
which containment strategies facilitated individuals
leading a normal life. Pre-specified subgroups were:
 UI: Defined as involuntary loss of urine according
to International Continence Society/International
Urogynecological Association terminology [21].
This profile included people experiencing stress
(SUI), urgency (UUI), and mixed (MUI) UI not
covered by the other categories.
 FI: Defined as loss of control of liquid or solid stool.
 Disabled persons and those with neurological
problems or diseases: Conditions including
Parkinson’s disease, multiple sclerosis, multiple
system atrophy, stroke, and spina bifida.
 Elderly or cognitively impaired: Defined as those ≥
65 years and those with, among other conditions,
Alzheimer’s disease.
Cure was defined as no leakage (UI) and/or no
episodes of FI at trial specified time points, of at least
3 months. Success rates for containment were defined as
the percentage of patients with no limitations to activ-
ities of daily living, quality of life, or social interaction.
Data sources and searches
Inclusion criteria
Studies of any design which included adult patients
(≥18 years) with UI or FI, reporting cure or success
rates, with ≥ 50 patients, evaluating any intervention in
line with the 5th International Consultation on Incontin-
ence (ICI) treatment algorithms [22] (which includes
primary, secondary and additional lines of therapy), a
follow-up time ≥ 3 months, and published between
January 2005 and June 2015 were included. Medline,
Embase, PsycINFO, the Cochrane Central Register of
Controlled Trials (CENTRAL), CINAHL, and PEDro
were searched. Supplementary searches were undertaken
for conference abstracts and trials registers published in
2014 and 2015 (Additional file 1).
Study selection
Titles and abstracts of retrieved references were
screened for relevance independently by two re-
viewers. Disagreements were resolved through discus-
sion or referral to a third reviewer where necessary.
References requiring further scrutiny were ordered
and full papers were screened for relevance independ-
ently by two reviewers. Disagreements were resolved
as for titles/abstracts.
Data extraction and quality assessment
Data extraction was performed independently by two
reviewers using an a priori designed data extraction
form. Disagreements were resolved through discussion
or referral to a third reviewer where necessary. The
Downs and Black checklist was used for quality assess-
ment [23]. The checklist has 28 questions that can each
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be answered with ‘Yes’ or ‘No’, indicating high or low
risk of bias; eight questions were not applicable, for
example, as we were only interested in the number of
patients with a certain outcome, variability is not an
issue (Questions 7 and 10). Questions that were of
specific relevance to the current review were Q2 – out-
come description, Q3 – description of patients included,
Q4 –description of the intervention, and Q12 – repre-
sentativeness of patients included. Quality assessment
was independently conducted by two reviewers. Dis-
agreements were resolved through discussion or referral
to a third reviewer where necessary.
Data synthesis and analysis
A narrative summary of all included studies, including a
summary of the characteristics (e.g. study design, sample
size, geographical location, year, baseline population
characteristics, outcome definition and assessments) and
methodological quality of the studies is presented. As
this review focuses on cure rates of different interven-
tions and subsequent dependence on containment prod-
ucts, and not the relative effectiveness of interventions
compared with each other, we included cure rates from
individual study arms. Cure rates are expressed in
percentages and are calculated as follows: number of
patients who had no leakage and/or no episodes of FI
divided by the total number of patients in the study
population at a given time point. Where possible, results
in the text are pooled by expressing the results as
medians with interquartile ranges (IQR) including re-
sults at all follow-up points (as reported in the summary
tables for each population), unless described otherwise.
If there were insufficient data to report medians, results
for individual studies are presented. In studies including
different populations, for instance, people with SUI and
UUI, cure rates for the specific population (UUI or SUI)
have been reported where possible; if this was not
possible, the cure rate for the whole population was
reported in the SUI and UUI sections.
Results
The searches retrieved 14,036 records. After title and ab-
stract screening, 846 references remained; these were or-
dered for full review and 8 were unobtainable. The
reasons for exclusion are listed in the flow chart (Fig. 1).
The most common reason for exclusion was that the
treatment was not deemed ‘according to the ICI
algorithms’ (603 records excluded); often because the
intervention was a second or third line treatment and
there was no description of previous interventions in
first or second line.
In total, 127 papers reporting on 98 individual studies
were included. Initially, 30 papers (24 studies) with a
follow-up of 12 weeks were excluded in accordance with
the protocol. However, after discussions with clinicians,
it was concluded that readers with a clinical perspective
would most likely consider 12 weeks and 3 months to be
equivalent, and therefore these 30 papers were included.
Forty-six studies were performed in Europe, 20 were
from North America and 15 were from centers on more
than one continent (Europe and America or Australia
and America). Forty-four studies included only female
patients and another 32 studies included more than 60%
female patients. The 98 studies included 150 interven-
tions (Additional file 2: Table S1). Most interventions
were surgically inserted tapes and slings (n = 45) or
pharmacological treatments (n = 45), 18 were PFMT
interventions. None of the included studies examined
success rates for containment strategies.
Most studies had at least 10 out of 20 items with low
risk of bias (Additional file 2: Table S2). Five studies had
more than 17 items with low risk of bias, and nine studies
had fewer than 10 items with low risk of bias. All studies
clearly described aims and objectives and, hence, were at
low risk of bias for question 1. Items with the most studies
scoring high risk of bias were Q15 – blinding of outcome
assessors, Q23 – random patient selection, and Q26 – loss
to follow-up explained. For all other items more than 80%
of studies were at low risk of bias.
Results are reported by patient profile (UI, FI, Disabled
and neurological problems or diseases, and Elderly or
cognitively impaired).
Studies in patients with UI
Interventions for SUI reported a median cure rate of
32% (IQR, 28–36%) for open colposuspension and 82.3%
(IQR, 72–89.5%) for other surgical techniques. UUI,
mostly treated by pharmacological means, had a median
cure rate of 45.8% (IQR, 35.6–57.8%) for drug treat-
ments, depending on the drug used. MUI demonstrated
intermediate cure results, falling between those for SUI
and UUI, depending on the nature of the underlying
condition and the intervention employed.
SUI
Forty-four studies looked at 67 interventions in patients
with SUI. Thirty-four studies were predominantly in
women, eight studies were predominantly in men; in
two studies, gender was not reported (Additional file 2:
Tables S3 and S4). Thirty-five studies were specifically in
patients with SUI, seven studies included patients with
MUI and SUI, one study included patients with UUI and
SUI, and one study included patients with UUI, MUI
and SUI.
Results are reported in Additional file 2: Table S5 and
an overview of the summary of cure rates is reported in
Table 1. All cure rates for all follow-up points within each
study reported in the included studies are listed in
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Additional file 2: Table S5. The summary table
(Table 1) lists all cure rates at the final follow-up for
each study. In the text below, pooled results for each
intervention are reported as specified in the Methods
section.
The majority of the studies evaluating different in-
terventions for patients with SUI reported follow-up
at 3, 6 and 12 months. At 12 months, the median
cure rate for surgical interventions for women was
84.4% (IQR, 74–90.1%). For men, results for male
slings were reported for up to 3 years’ follow-up, with
a median cure rate over all follow-up periods of 53%
(IQR, 48–54%). One study examined supervised
PFMT for women and found a cure rate of 58.8% at
12 months. For men, the cure rates for PFMT at 3
and 6 months were 51.9% and 78%, respectively.
Treatment with injectable bulking agents showed cure
rates of 24.8% and 36.9% at 12 months’ follow-up.
UUI
Thirty-two studies looked at 54 interventions for patients
with UUI (Additional file 2: Tables S6 and S7). Eight of the
32 studies were in women only, 22 of the remaining 24 stud-
ies included more than 60% women. The remaining two
studies only included men. Two studies included patients
with MUI and UUI [24, 25], one study included UUI and
SUI [26], and one study included SUI, MUI and UUI [27].
Results are reported in Additional file 2: Table S8 and
an overview of the summary of cure rates is reported in
Table 2. All cure rates for all follow-up points within
each study reported in the included studies are listed in
Additional file 2: Table S8. The summary table (Table 2)
Fig. 1 Summary of study flow
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lists all cure rates at the final follow-up for each
study. In the text below, pooled results for each
intervention are reported as specified in the Methods
section.
Most studies for patients with urgency UI evaluated
pharmacological interventions and had follow-up of
less than 1 year (Table 2). The median cure rate for
antimuscarinics was 49% (IQR, 35.6–58%). For mira-
begron, cure rates of 47.1% were found at 3 months’
follow-up and of 43.4% and 45.8% at 12 months. Cure
rates of 15% and 17% were seen at 5 and 10 years,
respectively, for sacral neuromodulation for women
with UUI. OnabotulinumtoxinA achieved cure rates
ranging from 15.9% for 50 U to 50.9% for 300 U at
3 months in one study, and 31.1% for 200 IU at
6 months in another study. These studies did not
include patients with neurogenic incontinence.
Supervised PFMT interventions were only evaluated in
men with UUI showing cure rates of 24% and 35% at
12 months.
MUI
Sixteen studies examined 23 interventions for patients
with MUI (Additional file 2: Tables S9 and S10), with 10
studies in women only, one including 38% men, one
including 20% men, and four including only male patients.
Seven studies included patients with SUI and MUI, two
studies included patients with MUI and UUI, and one
study included patients with all three types of UI; the
remaining six studies included patients with MUI.
Results are reported in Additional file 2: Table S11 and
an overview of the summary of cure rates is reported in
Table 3. All cure rates for all follow-up points within
each study reported in the included studies are listed in
Additional file 2: Table S11. The summary table (Table 3)
lists all cure rates at the final follow-up for each study.
In the text below, pooled results for each intervention
are reported as specified in the Methods section.
The median cure rate for surgical interventions for
women with MUI was 82.3% (IQR, 77.4–89.7%). The
median cure rate for supervised PFMT interventions in
Table 1 Cure ratesa in studies for female and male patients with stress urinary incontinence
Follow-up 3 m 6 m 12 m 18 m 2 y 3 y 5 y
Treatment – WOMEN
TVT 78% 50% 53%; 90.1% W 89.5% 81% W
92%
TVT-O 82.3%; 94.1%; 92.3%; 76%;
88.4% W; 88.8%
92.6% 86.4%; 87%
72%
74%
TVT Surgery/Individually tailored/
MiniTape/SPARC
83.1% W (Primus) 27.7% W (North) 85%; 82% (VL) 31.6% W (North)
82.3% W (Primus) 32.3% W (North)
84.4% W (Primus)
TOT 82.8% 84.3% 63.4%; 74%; 88.6%; 93.3% 65%
Retropubic TVT 89.7% 86.1%; 65.5%; 81% 80.1% 77.4%
Sling 94.1% 92.2% W; 81.3% 81.2%; 90.8%; 90.1% W;
63.7%; 90.2%; 92.2%; 41%
52.8% 83.7%; 50.5%
89.8%; 81%; 44%
Colposuspension 22%/32% 90% W
28%/36%
Other (surgery) 79%
PFMT – supervised 52.9%; 5% 58.8%
Vaginal cone therapy 9%
Lifestyle advice – unsupervised 8%
Injectable bulking agents 36.9%; 24.8%
Duloxetine NR
Treatment – MEN
Male sling 80% 55.8% W 58% W; 51.4% W; 53.8% 42.5% 48% W; 54% W 40% W; 53%
PFMT – supervised 51.9% 78%
PFMT – unsupervised NR
PFMT – supervised + drug 78% 62%
aCure defined as ‘cure’, ‘objective cure’, or ‘success (dry)’
BI behavioral interventions; NR not reported; PFMT pelvic floor muscle training; TOT transobturator tape; TVT tension-free vaginal tape; TVT–O tension-free vaginal
tape–obturator; W with containment products; VL Van Leijsen 2013; North North 2010; Primus Primus 2006
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men was 47% (IQR, 35–66.7%); for women, cure rates of
25% at 3 months and 28% at 6 months were reported.
No studies meeting inclusion criteria were found for
the following interventions for UI: scheduled voiding
(bladder training), continence products, artificial urinary
sphincter, α-blockers, 5-alpha-reductase inhibitors (5ARI),
correcting anatomic bladder outlet obstruction, intermit-
tent catheterization, or bladder augmentation.
Studies in patients with FI
Eleven studies examined 12 interventions for patients
with FI (Additional file 2: Table S12 and S13), one study
in women only, nine with more than 77% women, and
one where the majority of included participants was
male (85%).
Results are reported in Additional file 2: Table S14 and
an overview of the summary of cure rates is reported in
Table 4. All cure rates for all follow-up points within
each study reported in the included studies are listed in
Additional file 2: Table S14. The summary table (Table 4)
lists all cure rates at the final follow-up for each study.
In the text below, pooled results for each intervention
are reported as specified in the Methods section.
The median cure rate for female patients with FI
following sacral neuromodulation was 38.6% (IQR, 35.6–
40.6%). Methylcellulose plus loperamide was assessed in
one study, with a cure rate of 46% at 3 months. In men,
cure rates for biofeedback were 40.8% at 6 months,
35.8% at 3 years and 29% at 5 years’ follow-up.
No studies meeting inclusion criteria were found for
the following interventions for FI: education of patient
and/or caregiver, diet and eating pattern modifications,
dietary fiber supplements, bowel habit training, rectal
irrigation, continence products such as pads or anal plug
for containment, PFMT, sphincteroplasty, artificial bowel
sphincter, dynamic graciloplasty, antegrade continence
enema, colostomy, magnetic anal sphincter, and pubor-
ectal sling.
Studies in patients with incontinence due to neurological
problems or diseases
Four studies were identified in patients with neurological
problems or diseases. Of these, two studies included
neurological patients with UI and the remaining two
studies included those with FI (Additional file 2: Table
S15 and S16).
Results are reported in Additional file 2: Table S17 and
an overview of the summary of cure rates is reported in
Table 5. All cure rates for all follow-up points within
each study reported in the included studies are listed in
Additional file 2: Table S17. The summary table (Table 5)
lists all cure rates at the final follow-up for each study.
Table 2 Cure ratesa in studies for female and male patients with urgency urinary incontinence
Follow-up: 3 m 6 m 12 m 18 m 2 y 3 y 5 y
Treatment – WOMEN
Antimuscarinic 21%
Darifenacinb 38% 41% 42% 43.8%
Fesoterodine 63%; 62%; 64%; 49.2%; 57.8%
Oxybutynin 25.2%; 20%
Solifenacin 58%; 59%; 56.2%; 59.6% 11% 58%
Tolterodine 13%; 56%
57.2%; 49%
70% 45.1%
Tolterodine + BI NR
Trospium 35.6%; 20.5%
Adrenergic drugs (Mirabegron) 47.1% 43.4%; 45.8%
Neuromodulation 39% 15% (10 y: 17%)
Neuromodulation + PFMR 93% 39% 15% (10 y: 17%)
TVT 92%
Botulinum toxin 35%; 22.9%
15.9–50.9%
31.3%
Treatment – MEN
Solifenacin + Tamsulosin NR
PFMT – supervised 24%; 35%
Lifestyle advice – unsupervised 23%; 38%
aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’, or complete continence
bReductions of ≥ 90% from feeder-study baseline in incontinence episodes/week
BI behavioral interventions; NR not reported; PFMT pelvic floor muscle training; TVT tension-free vaginal tape
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In the text below, pooled results for each intervention
are reported as specified in the Methods section.
Only one study reported a cure rate beyond 3 months,
showing 9% cure for FI at 18 months with transanal
irrigation. Cure rates for urinary voiding programs (VP)
were 41% (VP alone) and 31% (VP and supported imple-
mentation) at 3 months’ follow-up.
No studies were found for the following interventions
for UI in patients with neurological problems or diseases:
behavioral modification, external appliances, intermittent
catheterization (with or without antimuscarinics), behav-
ioral modification, antimuscarinics, continence products,
indwelling catheter, alpha 1 adrenergic blockers, straining,
triggered voiding, artificial sphincter, bladder neck sling,
autologous sling, bladder neck closure, intraurethral
stents, transurethral incision sphincter, sacral deafferen-
tation, and enterocystoplasty.
No studies were found for the following interven-
tions for FI in patients with neurological problems
or diseases: containment products (such as anal
plugs), patient education, adequate fiber diet and
fluid intake, manual evacuation, mini-enema, digital
rectal stimulation, chemical stimulant, fecal disim-
paction, antegrade continence enema, graciloplasty,
Table 4 Cure ratesa in studies for female and male patients with fecal incontinence
Follow-up: 3 m 6 m 12 m 18 m 2 y 3 y 5 y
Treatment – WOMEN
Biofeedback NR
Sacral neuromodulation 38.6%; 38.9% 31.7%; 39.3% 41.5%/47.2%; 40.6% 26% 37.3% 41.7% 4 y: 35.6% 36.1%
Peripheral stimulation NR
Methylcellulose + loperamide 46%
Injectable bulking agents NR NR
Standard conservative treatment NR
Treatment – MEN
Biofeedback 40.8% 35.8% 29%
aCure defined as ‘cure’, ‘objective cure’, or ‘100% improvement in incontinence episodes per week’
NR not reported
Table 3 Cure ratesa in studies for female and male patients with mixed urinary incontinence
Follow-up 3 m 6 m 12 m 18 m 2 y 3 y 5 y
Treatment – WOMEN
TVT NR
Retropubic TVT 89.7% 86.1% 80.1 77.4%
SPARC 83.1% W 82.3% W 84.4% W
Sling 94.1% 81.3%; 89.8% 63.7%; 90.2% 52.8% 50.5%; 83.7%;
PFMT – supervised 5% NR 8 y: NR
PFMT + neuromodulationb 93%
PFMT + lifestyle advice 25% 28%
Vaginal cone therapy 9%
PFMT – supervised + delivery 17%
Lifestyle advice (supervised) 8%
Solifenacin 52%
Duloxetine NR
Treatment – MEN
Solifenacin 26.5%
PFMT – supervised 44%; 46.3% 47%; 66.7% 24%; 35%; 60%; 83.4%
PFMT – unsupervised 40% 50% 64%
Lifestyle advice – unsupervised 23%; 38%
aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’ or complete continence
bSuccess, defined as ‘An absence of incontinent episodes (dry) and an OAB-V8 score < 8, indicating no OAB’
NR not reported; PFMT pelvic floor muscle training; TVT tension-free vaginal tape; W with containment products
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artificial anal sphincter, sacral anterior root stimula-
tion, botulinum toxin, and neuromodulation.
Studies in elderly or cognitively impaired patients with
incontinence
Four trials were identified in elderly patients with incon-
tinence; no studies were found for patients with cogni-
tive impairments (Additional file 2: Table S18 and S19).
Results are reported in Additional file 2: Table S20
and an overview of the summary of cure rates is re-
ported in Table 6. All cure rates for all follow-up
points within each study reported in the included
studies are listed in Additional file 2: Table S20. The
summary table (Table 6) lists all cure rates at the
final follow-up for each study. In the text below,
pooled results for each intervention are reported as
specified in the Methods section.
None of the studies reported cure rates beyond 3 months’
follow-up. The only cure rates reported were 50.8% for
fesoterodine and 33% and 49% for darifenacin for UI at
3 months’ follow-up.
No studies were found for the following interventions
for UI or FI in older men and women: continence
products, lifestyle interventions, behavioral therapies,
and biofeedback. None of the included studies looked at
cure or success rates for containment strategies.
Discussion and conclusions
Summary of main results
We included 98 individual studies evaluating 150 in-
terventions. Five studies had more than 17 items with
low risk of bias, indicating these are probably the
most reliable studies; nine studies had fewer than 10
items with low risk of bias, probably indicating that
these are the least reliable studies. However, these as-
sessments were based on the available information for
the study; a low score may reflect poor reporting (for
example, due to lack of space in conference abstracts)
rather than a poor study.
Surgical techniques for SUI resulted in a median cure
rate of 82.3% (IQR, 72–89.5%). Patients with UUI were
mostly treated pharmacologically, with a median cure
rate for antimuscarinics of 49% (IQR, 35.6–58%), de-
pending on the medicine used. MUI demonstrated re-
sults between SUI and UUI, depending on the nature of
the underlying condition and the intervention employed.
For patients with FI, most studies evaluated sacral
neuromodulation, which showed a median cure rate of
38.6% (IQR, 35.6–40.6%).
For patients with neurological problems or diseases,
very few interventions were evaluated, with cure rates
for FI of 9% for transanal irrigation at 18 months’
follow-up, and 31% and 41% for VPs.
For elderly patients with incontinence, only antimus-
carinics were evaluated at 3 months’ follow-up, with cure
rates of 50.8% for fesoterodine, and 32.7% and 48.5% for
darifenacin. No studies were found for patients with cog-
nitive impairments.
No studies were found that assessed the ability of con-
tainment strategies to support people with incontinence
in leading normal lives.
Treatment complications and adverse events
This systematic review focused on cure rates for the
treatment of incontinence. However, it is also important
to recognize that there are unintended consequences of
the evaluated interventions, especially in light of the
current debate of surgical meshes.
The European Union’s Scientific Committee on
Emerging and Newly Identified Health Risks (SCENIHR)
published an Opinion on the safety of surgical meshes
used in urogynecological surgery in December 2015
[28]. The SCENIHR acknowledged the efficacy and use
of implanted meshes for SUI in the majority of patients
with moderate to severe SUI. It considered that the
associated risk was limited, but recognized the absence
of long-term data. Further, it commented that the risk of
severe side effects (e.g. mesh exposure, shrinkage, pain)
increases with the surface area of synthetic non-
absorbable meshes, so that vaginally-implanted mesh for
Table 5 Cure ratesa in studies for female and male patients
with neurological problems or diseases
Follow-up: 3 m 6 m 12 m 18 m 2 y 3 y 5 y
Treatment – WOMEN
Botulinum toxin NR
Peripheral stimulation NR
Transanal irrigation 9%
Voiding program 41%; 31%
Usual continence care 30%
Treatment – MEN
None
aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’, or ‘100% improvement in
incontinence episodes per week’
NR not reported
Table 6 Cure ratesa in studies for elderly or cognitively
impaired patients with incontinence
Follow-up 3 m 6 m 12 m 18 m 2 y 3 y 5 y
WOMEN & MEN – Antimuscarinics
Fesoterodine 50.8% NR
Darifenacin 48.5%; 32.7%
WOMEN & MEN – Botulinum toxin
Onabotulinumtoxin A NR NR NR
aCure defined as ‘cure’, ‘objective cure’, ‘success (dry)’, or ‘100% improvement in
incontinence episodes per week
NR not reported
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pelvic organ prolapse is associated with increased risks
compared with mesh implantation for SUI.
Treatment of UUI was mainly with antimuscarinic
drugs. These may cause a range of side effects such as
dry mouth, gastrointestinal disturbances including con-
stipation and flatulence, taste disturbances, blurred
vision, dry eyes, drowsiness, dizziness, fatigue, difficulty
in micturition (less commonly urinary retention),
palpitation, and skin reactions [29]. Different antimus-
carinic drugs differ in the level of adverse events seen
[30]; only 14–35% of community dwelling patients still
take antimuscarinic treatments 12 months after starting
treatment [31].
Non-pharmacological treatments for UUI included
PFMT. A Cochrane review [32] found only one trial
reporting adverse events [33], comprising pain (one par-
ticipant), uncomfortable feeling during exercise (three
participants) and ‘not wanting to be continuously both-
ered with the problem’ (two participants).
Sacral neuromodulation for UUI can also cause ad-
verse events, with 53% of patients in one trial [34]
experiencing a range of adverse events. While this is a
high rate of adverse events, it should be noted that the
other studies cited in this discussion section examined
different patient populations, making a direct compari-
son problematic.
Information on adverse events in treatments for FI
was less extensive than for UI. Christensen et al. [35]
carried out an audit of bowel perforations related to
transanal irrigation using the Peristeen Anal Irrigation®
system. A total of 49 such reports were found, corre-
sponding to an average risk of bowel perforation of 6
per million procedures. In a review of 10 years of
experience in a tertiary referral center between 2005
and 2015, out of 58 patients undergoing sacral neuro-
modulation system implantation Koh et al. [36] re-
ported four postoperative complications (7%) including
three wound infections and one lead migration, of
which three required sacral nerve stimulation reinser-
tion. Adverse events of injectable bulking agents have
also been described, including injection-site infection,
fever, pain/proctalgia, prolonged defecation, and rectal
hemorrhage [37].
Strengths and limitations, including lack of evidence for
missing interventions
The main strength of this review was an extensive search
of the most relevant databases, conference proceedings
and trial registers for a wide range of populations and
interventions. A wide range of different outcomes on
cure at different follow-up times, ranging from 3 months
to 10 years was extracted making this one of the most
complete overviews of cure rates for incontinence inter-
ventions to date.
Limitations included the lack of evidence for the speci-
fied populations for specific interventions (for instance,
artificial sphincter for patients with UI) and for long-
term follow-up (beyond 1 year). In some areas, evidence
may have seemed limited as the bulk of relevant research
was carried out before 2005 and was therefore excluded.
In particular for FI, few studies could be included be-
cause trials are typically small (fewer than 50 partici-
pants), or ‘cure’ is often not reported, especially as most
FI scores are composite and include flatus incontinence.
For patients with UI, the success of treatment depended
greatly on the type of incontinence experienced, with
treatment methods playing a significant part. For instance,
for patients with SUI, the most common treatment were
tapes and slings, with cure rates mostly between 60% and
90%, and for patients with UUI, the most common
treatment was antimuscarinics, with cure rates mostly
between 30% and 60%.
Furthermore, a critical factor to consider is the study
population, for example, whether the population is treat-
ment naïve or has failed prior therapy. In this review, all
treatments were evaluated in line with their place in the
treatment algorithms of the 5th ICI [22]. Therefore, for
any second line therapies, such as botulinum toxin and
sacral neuromodulation, patients will have failed primary
therapy. Additionally, the diagnosis of mixed incontin-
ence is often left to the discretion of the investigator,
which may have led to differences between studies.
Additional limitations were the wide range of popula-
tions included in the studies, even within specific groups
of patients, and the differences between interventions
and differences between outcome measures reported.
Where possible, we focused on reported objective cure
rates. However, studies used different definitions of
objective cure. For example, ‘completely dry’, ‘a negative
cough stress test’, and ‘normal detrusor function during
filling cystometry’ were all definitions used in patients
with SUI.
Overall conclusions
Most evidence was found for UI with a median cure rate
of 82.3% (IQR, 72–89.5%) for surgical interventions for
SUI. Cure rates with PFMT (ranging from 5% to 83.4%
in all populations) and injectable bulking agents (24.8%
and 36.9%) were lower. Most of the studies reporting
cure with drugs were found for patients with UUI,
almost exclusively with short-term follow-up (3 months)
(median cure rate for antimuscarinics: 49%; IQR, 35.6–
58%). For patients with FI, most studies evaluated sacral
neuromodulation, revealing a median cure rate of 38.6%
(IQR, 35.6–40.6%).
Thus, based on this systematic review, a large propor-
tion of individuals treated for incontinence were not cured
and may continue to rely on containment strategies, such
Riemsma et al. BMC Medicine  (2017) 15:63 Page 9 of 11
as behavioral strategies and containment products. There
was an absence of studies assessing the extent to which
different types of behavioral and containment strategies
supported people in leading a normal life. A number of
pharmacological studies in UUI assessed reduction in pad
use as a secondary outcome but none reported the extent
of this reduction in the exposed population.
Research/policy recommendations
Blinding of outcome assessors, random patient selection,
and loss to follow-up were most often poorly reported,
leading to risk of bias in the included studies. Future
studies should report clearly on these items.
Very few combinations of interventions were found.
Further evaluation of combination interventions for both
UI and FI is warranted.
Evidence is lacking for interventions in people with in-
continence due to neurological problems or diseases and
for older adults and those persons with cognitive impair-
ment, and research in these populations is therefore
warranted.
Cure is important but there needs to be a better
understanding of what types of containment strategies
can best support a normal social life when cure is not
achieved, and which types of containment strategy will
be most beneficial for which type of person with
incontinence. Further research regarding the ability of
containment to improve the daily lives of individuals
with incontinence is therefore required.
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